3 Results for "

Spartalizumab

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "Spartalizumab" in MCE Product Catalog:

Cat. No.: HY-P9972
CAS No.: 1935694-88-4
Synonyms: PDR001

Target:  

PD-1/PD-L1 IFNAR

Research Areas:  

Cancer

Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-109139
CAS No.: 1337962-47-6
Purity:  99.84%
Synonyms: NIR178; PBF509
Target:  

Adenosine Receptor

Research Areas:  

Neurological Disease Cancer

Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A2A receptor (A2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparkinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response .
loading...
    loading...
Cat. No.: HY-109139R
CAS No.: 1337962-47-6
Synonyms: NIR178 (Standard); PBF509 (Standard)
Taminadenant (Standard) is the analytical standard of Taminadenant (HY-109139). This product is intended for research and analytical applications. Taminadenant (NIR178; PBF509) is a highly potent and orally active adenosine A2A receptor (A2AR) antagonist. Taminadenant can antagonize A2AR agonist-mediated cAMP accumulation and impedance responses with KB values of 72.8 nM and 8.2 nM, respectively. Taminadenant reverses motor impairments in several rat models of movement disorders, including catalepsy, tremor, and hemiparKinsonism. Taminadenant can also inhibit tumor growth when combined with Spartalizumab (HY-P9972). Taminadenant reactivate the antitumor immune response .
loading...
    loading...